

Roche, Eli Lilly and Sanofi discuss biophysical tools in drug design

Roche, Eli Lilly and Sanofi will meet at the 15th Annual Advances and Progress in Drug Design Conference to discuss biophysical tools in drug design



LONDON, UNITED KINGDOM, November 24, 2015 /EINPresswire.com/ -- Griffith University's Institute for Glycomics made scientific history by determining the first 3-D image of a [protein](#) linked to the spread of cancer. Structural and functional determination of the enzyme made it the first reported heparanase X-Ray crystal structure in the world, enabling further research into structure-guided anti-cancer and anti-angiogenesis inhibitor discovery. (Source - Scicasts 2015)

With the latest industry updates, SMi Group is proud to announce Roche, Eli Lilly and Sanofi will meet at the 15th Annual Advances and Progress in [Drug Design](#) Conference to discuss [biophysical](#) tools in drug design.

Amin Ruf, Section Head Biostructure, Roche will explain high resolution for drug discovery. His presentation will give a follow up on X-ray crystallographic from high throughput of fragment screening and advantages of obtaining X-ray complex structures early and at high resolution.

Biophysical technologies in drug discovery - bringing different approaches in drug design to identify and optimise meaningful drug lead compounds will be presented by Manuel Molina, Research Scientist, Eli Lilly. The case study will give an overview of opportunities in biophysical screening to catch up with FBDD techniques.

Alexey Rak, Head of Bio Structure and Biophysics at Sanofi will discover biophysical screening tools for compound validation. He will focus on small molecule probes to elucidate structural information and early validation.

This year's Advances and Progress in Drug Design event will focus on enabling biophysical tools and highlight key advancements in protein-based drug discovery. It will take a closer look at combined HTS and FBDD methods for lead generation and the application of biophysical methods such as: X-Ray Crystallography, NMR, biocore and ITC to aid the prioritization of target inhibitors.

Plus, two interactive half-day post-conference workshops:

- A fresh view on molecular recognition: the dynamic perspective – presented by Barcelona University
 - Analysis and Application of Ligand Conformation in Drug Design – presented by C4X Discovery
- Those who are interested in attending are advised to register before 30th November to secure the place at the conference and save £200.

For the full event agenda/ to register please visit: www.drug-design.co.uk/ein

Alternatively, get in touch with Matthew Apps: +44 20 7827 6093 or e-mail: mapps@smi-online.co.uk

----- END -----

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Anna Serazetdinova
SMi Group Ltd
+44702078276180
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2015 IPD Group, Inc. All Right Reserved.